Literature DB >> 24827504

Prostate cancer: BETting on epigenetic therapy.

Sarah Seton-Rogers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24827504     DOI： 10.1038/nrc3750

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

1.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962
  1 in total
  2 in total

Review 1.  BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.

Authors:  Sarah E Lochrin; Douglas K Price; William D Figg
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

2.  Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems.

Authors:  Yipeng Xu; Gabriela Pachnikova; Dorothea Przybilla; Reinhold Schäfer; Yingying Cui; Dan Zhou; Zihao Chen; An Zhao; Ulrich Keilholz
Journal:  Front Pharmacol       Date:  2022-02-03       Impact factor: 5.810
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.